Breaking News, Collaborations & Alliances

Isis Earns 18M GSK Milestone

Advances Phase II/III of ISIS-TTRRx in familial amyloid polyneuropathy

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned an $18 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). The Phase II/III study aims to support an application for marketing approval of ISIS-TTRRx in FAP. The study will measure the effects of ISIS-TTRRx on neurological dysfunction and on quality-of-life.    ISIS-TTRRx is an antisense drug for the treatment of transthyretin amyloidos...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters